

## HEMATOPOIESIS AND STEM CELLS

# Murine AGM single-cell profiling identifies a continuum of hemogenic endothelium differentiation marked by ACE

Muhammad Zaki Hidayatullah Fadlullah,<sup>1,\*</sup> Wen Hao Neo,<sup>1,\*</sup> Michael Lie-a-ling,<sup>1,\*</sup> Roshana Thambyrajah,<sup>2</sup> Rahima Patel,<sup>1</sup> Renaud Mevel,<sup>1</sup> Irène Aksoy,<sup>3</sup> Nam Do Khoa,<sup>4</sup> Pierre Savatier,<sup>3</sup> Laura Fontenille,<sup>4</sup> Syed Murtuza Baker,<sup>5</sup> Magnus Rattray,<sup>5</sup> Valerie Kouskoff,<sup>6</sup> and Georges Lacaud<sup>1</sup>

<sup>1</sup>Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom; <sup>2</sup>Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Barcelona, Spain; <sup>3</sup>Université Lyon 1, INSERM, Stem Cell and Brain Research Institute U1208, Bron, France; <sup>4</sup>Azelead, Montpellier, France; and <sup>5</sup>Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health; and <sup>6</sup>Division of Developmental Biology & Medicine, The University of Manchester, Manchester, United Kingdom

## KEY POINTS

- Full-length scRNA-seq identifies a detailed pre-HE to HE maturation trajectory marked by ACE (CD143).
- Runx1b<sup>+</sup> subaortic cells can support hematopoietic activity and consist of smooth muscle and PDGFRα expressing mesenchymal cells.

**In vitro generation and expansion of hematopoietic stem cells (HSCs) holds great promise for the treatment of any ailment that relies on bone marrow or blood transplantation. To achieve this, it is essential to resolve the molecular and cellular pathways that govern HSC formation in the embryo. HSCs first emerge in the aorta-gonad-mesonephros (AGM) region, where a rare subset of endothelial cells, hemogenic endothelium (HE), undergoes an endothelial-to-hematopoietic transition (EHT). Here, we present full-length single-cell RNA sequencing (scRNA-seq) of the EHT process with a focus on HE and dorsal aorta niche cells. By using *Runx1b* and *Gfi1/1b* transgenic reporter mouse models to isolate HE, we uncovered that the pre-HE to HE continuum is specifically marked by angiotensin-I converting enzyme (ACE) expression. We established that HE cells begin to enter the cell cycle near the time of EHT initiation when their morphology still resembles endothelial cells. We further demonstrated that RUNX1 AGM niche cells consist of vascular smooth muscle cells and PDGFRα<sup>+</sup> mesenchymal cells and can functionally support hematopoiesis. Overall, our study provides new insights into HE differentiation toward HSC and the role of AGM RUNX1<sup>+</sup> niche cells in this process. Our expansive scRNA-seq datasets represents a powerful resource to investigate these processes further.**

functionally support hematopoiesis. Overall, our study provides new insights into HE differentiation toward HSC and the role of AGM RUNX1<sup>+</sup> niche cells in this process. Our expansive scRNA-seq datasets represents a powerful resource to investigate these processes further.

## Introduction

Hematopoietic stem cells (HSCs) sit at the apex of the blood system and are powerful treatment modalities for cancer and blood malignancies.<sup>1,2</sup> Understanding the molecular programs underpinning their formation during embryogenesis is critical for the development of efficient protocols to generate and amplify HSCs in vitro. In mice, the first transplantable HSCs are generated intra-embryonically in the region of the aorta-gonad-mesonephros (AGM) between embryonic day 10.5 (E)10.5 to E11.5.<sup>3-5</sup> Within this narrow time window, specialized endothelial cells lining the dorsal aorta (DA), known as hemogenic endothelium (HE), transition to nonadherent hematopoietic cells via a process termed the endothelial-to-hematopoietic transition (EHT).<sup>6-10</sup> Morphologically, the EHT produces intra-aortic hematopoietic clusters (IAHC) protruding from the endothelium into the lumen of the DA and other major arteries.<sup>11-13</sup> Although HE is established as the cellular source of the first blood cells in vivo and in vitro,<sup>8,10,14</sup> our knowledge of the molecular and cellular mechanisms regulating HSC emergence from HE remains incomplete.

The transcription factor RUNX1 controls the initiation and completion of EHT and is essential for establishing definitive hematopoiesis.<sup>15-19</sup> The downstream RUNX1 target genes *Gfi1/Gfi1b* encode critical regulators of EHT that recruit histone-modifying complexes to silence the endothelial program in HE.<sup>20,21</sup> The sequential expression of the transcriptional repressors GFI1/1B marks distinct stages of the EHT. GFI1 is expressed in HE, whereas GFI1B is mainly found in IAHC.<sup>21</sup> In contrast, RUNX1 expression is detected during all stages of EHT.<sup>22,23</sup> Additionally, RUNX1 expression is also found in subaortic mesenchyme.<sup>5,22,24</sup> The exact identity and the potential role of these mesenchymal RUNX1<sup>+</sup> cells are currently unknown.

Single-cell RNA sequencing (scRNA-seq) is a powerful tool to profile developmental pathways. Although this can now be done globally on whole organs and organisms,<sup>25-29</sup> understanding pathways involving rare cell populations still greatly benefits from targeted approaches using enriched cell populations. We and others have previously taken the latter approach to start

resolving molecular events leading up to HSC formation in the murine AGM.<sup>30-35</sup> Much emphasis has been on the final steps of HSC commitment within the IAHC.<sup>11,31,33,35</sup> However, the intricacies of DA HE differentiation before the initiation of EHT are not well defined. Reasons for this are the rarity of the HE population but also a lack of suitable cell surface markers for HE purification.

To gain insight into how DA HE progresses toward EHT, we used 2 transgenic reporter mouse models (*Runx1b<sup>RFP</sup>* and *Gfi1<sup>Tomato</sup>/Gfi1b<sup>GFP</sup>*)<sup>20,21,23,36,37</sup> to isolate and profile a wide variety of phenotypic HEs. We reasoned that targeted scRNA-seq of *Runx1b:RFP<sup>+</sup>* and *Gfi1:Tomato<sup>+</sup>* phenotypic HE populations is essential to profile them in-depth because they represent only a small fraction of the total CDH5<sup>+</sup> endothelial populations in the AGM (~6% and 0.6%, respectively; supplemental Figure 1, available on the *Blood* Web site). We also profiled *Runx1b:RFP<sup>+</sup>* AGM mesenchymal cells. To maximize data recovery, we adopted a full-length scRNA-seq protocol.<sup>38,39</sup> The resulting dataset contains nearly 1200 fluorescence-activated cell sorted (FACS) cells, representing 9 E10.5 mouse AGM populations.

Our data capture a detailed HE differentiation continuum, covering pre-HE and HE stages. We found that this continuum is marked by angiotensin-I converting enzyme (ACE) expression and that pre-HE and HE can be discerned based on cell-cycle status. Additionally, we establish that the rare *Runx1b:RFP<sup>+</sup>* sub-aortic mesenchymal population supports hematopoiesis and consists of smooth muscle and PDGFRa<sup>+</sup> cells. This high-resolution single-cell data set covering HE and its surrounding niche in the mouse DA can be queried at [http://shiny.cruk.manchester.ac.uk/AGM\\_scRNA/](http://shiny.cruk.manchester.ac.uk/AGM_scRNA/).

## Materials and methods

### Mouse embryos

Mouse work was performed following the UK Animal Scientific Procedures Act 1986 and was approved by the Animal Welfare and Ethics Review Body of the Cancer Research UK Manchester Institute. *Gfi1<sup>GFP</sup>/Gfi1b<sup>GFP</sup>*, *Gfi1<sup>Tomato</sup>/Gfi1b<sup>GFP</sup>*, and *Runx1b<sup>RFP</sup>* lines have been described previously.<sup>20,21,23,36</sup> Embryos were genotyped and processed as previously described.<sup>20,21,23</sup> Genotyping primers are listed in supplemental Table 1 (available on the *Blood* Web site).

### Zebrafish experiments

Zebrafish work was performed by Azelead (France) following the EU guidelines for handling laboratory animals and was approved by the Animal Care and Use Committee (APAFIS#21063). Transgenic lines *Tg(cd41:eGFP)* and *Tg(kdrl:caax-mCherry)* have been described previously.<sup>40,41</sup> Antisense *ptn* morpholino: 5'-CTGTAGTCTGAGGAATAGTTTGGTT-3' (GeneToolsLLC), negative control morpholino: 5'-CCTCTTACCTCAGTTACAATTATA-3' or vehicle was injected into single-cell embryos, as previously described.<sup>42</sup> Embryos were imaged using a Zeiss LSM510 and CellDiscoverer7.

### Flow cytometry

LSR Fortessa X20, ArialIII, and FlowJo (BD Biosciences) were used for FACS analysis and sorting. Antibodies are listed in supplemental Table 1.

## Ex vivo AGM assays

Reaggregation experiments: AGM cells were FACS depleted of the target population and reaggregated for 4 days in hanging drop culture as previously described.<sup>21</sup> Aggregates were trypsinized and analyzed in colony-forming unit (CFU) assays as previously described.<sup>43</sup> Coculture experiments: FACS isolated AGM cells were cocultured with vascular niche cells for 10 days as previously described.<sup>21,44,45</sup>

## scRNA-seq and data processing

Cells were sorted into lysis buffer and snap-frozen. Libraries were prepared using a modified Smart-Seq2 protocol described previously<sup>46</sup> and 38 bp or 75 bp paired-end sequenced on an Illumina NextSeq 500. FASTQ data were mapped to GRCm38 using STAR.<sup>47</sup> Count matrix was obtained with HTSeq<sup>48</sup> and loaded into the R environment with Scater.<sup>49</sup> Published scRNA-seq data<sup>32,34</sup> was downloaded from GEO (GSE112642, GSE137116). Detailed workflows are in the supplemental Methods.

## Immunofluorescence

Embryos fixed in 4% formaldehyde were embedded in paraffin or snap-frozen. Staining and processing of frozen sections has been described previously.<sup>21,50</sup> Staining of paraffin-embedded sections was performed on the Leica BOND RX as previously described.<sup>51</sup> Antibodies are listed in supplemental Table 1. Image analyses were performed with QuPath<sup>52</sup> (version 0.2.3).


## Results

### Full-length scRNA-seq improves data recovery

To determine if full-length scRNA-seq (Smart-seq2) offers significant advantages over 3'-based scRNA-seq, we used the same sorting strategy that we previously employed for 3'-based scRNA-seq of AGM cells.<sup>32</sup> Briefly, we FACS isolated cell populations encompassing the EHT from *Gfi1<sup>Tomato</sup>/Gfi1b<sup>GFP</sup>* reporter mice<sup>21</sup> (supplemental Figure 2A-B). The following E10.5 and E11.5 AGM populations were FACS isolated and sequenced using Smart-seq2<sup>38,39</sup>: non-HE/endothelial cells (FACS-ENDO<sup>Gfi1-het</sup>: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Gfi1:Tomato<sup>-</sup>Gfi1b:GFP<sup>-</sup>), HE (FACS-HE<sup>Gfi1-het</sup>: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Gfi1:Tomato<sup>+</sup>Gfi1b:GFP<sup>-</sup>), cells undergoing EHT (FACS-EHT<sup>Gfi1-het</sup>: CD41<sup>low</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>+</sup>Gfi1:Tomato<sup>+</sup>Gfi1b:GFP<sup>-</sup>), and IAHC (FACS-IAHC<sup>Gfi1-het</sup>: CD41<sup>low</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>+</sup>Gfi1:Tomato<sup>+</sup>Gfi1b:GFP<sup>+</sup>) (Figure 1A; supplemental Figure 2C-D). A total of 456 cells were sequenced with a median depth of >1 million sequencing reads/cell with >90% mapping (supplemental Figure 3A). Compared with our previous 3'-study,<sup>32</sup> we detected more genes (median: 5365 per cell vs 2498 per cell), lower dropout (median: 43% vs 76%), and increased coverage across transcripts (supplemental Figure 3B-D). This overall increased sensitivity is illustrated by the improved detection of *Gfi1/1b* transcripts (supplemental Figure 3E). Together, these data show that full-length scRNA-seq has clear benefits over 3'-based scRNA-seq.

### E10.5 and E11.5 phenotypic HE displays distinct transcriptional profiles

HE can be enriched by sorting cells coexpressing CDH5/VE-Cadherin and GFI1. Such double-positive cells are detected at a similar frequency in E10.5 and E11.5 AGMs.<sup>21</sup> It is currently unclear if these phenotypically identical HE populations are



**Figure 1. Distinct profile of E10.5 and E11.5 phenotypic HE.** (A) Schematic representation of cell populations at different stages of EHT in dorsal aorta (DA) alongside corresponding phenotypic markers used for FACS single-cell sorting. (B) Uniform Manifold Approximation and Projection (UMAP) plots showing all the cells

transcriptionally identical. Uniform Manifold Approximation and Projection (UMAP)<sup>53</sup> visualization of the sequenced FACS populations identified 6 robust clusters (C1-C6) (Figure 1B; supplemental Figure 4A-D; supplemental Table 2). C1, containing the bulk (71%) of the E10.5/E11.5 FACS-ENDO<sup>Gfi1-het</sup> cells, clustered away from all other clusters and mainly consisted of cells with a venous endothelial transcriptome (Figure 1B; supplemental Figure 4E,F). FACS-ENDO<sup>Gfi1-het</sup> cells with an arterial endothelial (AE) transcriptome resided in C2, which clustered closer to the EHT continuum (Figure 1B; supplemental Figure 4E,F).

FACS-HE<sup>Gfi1-het</sup> cells contributed to 3 clusters (C2-C4) (Figure 1C) that likely represent HE cells entering EHT. They shared similar expression of endothelial genes (*Cdh5*, *Kdr*, *Gja4*), whereas expression of hematopoietic genes (*Runx1*, *Itgb3*, *Myb*) increased from C2 to C4 (supplemental Figure 4G). The majority of E10.5 FACS-HE<sup>Gfi1-het</sup> was assigned to C3 and C4 and E11.5 FACS-HE<sup>Gfi1-het</sup> was mainly assigned to C2 and C3 (Figure 1C). Gene ontology analysis of the differential expressed genes (DEGs) between E10.5 and E11.5 FACS-HE<sup>Gfi1-het</sup> (supplemental Table 3) demonstrated that E11.5 FACS-HE<sup>Gfi1-het</sup> was characterized by endothelial/vascular gene ontology terms (Figure 1D). Known markers/regulators of arterial fate (*Notch1*, *Jag1*, *Sox7/17*, *Fbln5*)<sup>54-58</sup> were expressed higher in E11.5 FACS-HE<sup>Gfi1-het</sup> vs E10.5 FACS-HE<sup>Gfi1-het</sup> (Figure 1E). These data demonstrate that the phenotypically identical E10.5 and E11.5 FACS-HE<sup>Gfi1-het</sup> are transcriptomically different. E10.5 FACS-HE<sup>Gfi1-het</sup> cells display a robust hemogenic profile, whereas E11.5 FACS-HE<sup>Gfi1-het</sup> has a more pronounced arterial identity.

### Separation of E10.5 AGM cells into transcriptionally defined clusters

Having established that E10.5 FACS-HE<sup>Gfi1-het</sup> possesses a strong hemogenic transcriptional profile, we next sought to create a detailed scRNA-seq dataset representing early EHT in the E10.5 DA. We focused on capturing different stages of HE differentiation. Therefore, we expanded our E10.5 panel of FACS populations with phenotypic endothelial and HE cells from both heterozygote and homozygote *Runx1b*<sup>RFP</sup> as well as homozygote *Gfi1*<sup>GFP</sup>/*Gfi1b*<sup>GFP</sup> reporter mice (FACS-ENDO<sup>Runx1b-het</sup>, FACS-ENDO<sup>Runx1b-KO</sup>, FACS-HE<sup>Runx1b-het</sup>, FACS-HE<sup>Runx1b-KO</sup>, and FACS-HE<sup>Gfi1/1b-KO</sup>) (Figure 2A; supplemental Figures 2 and 5). The existence of a subpopulation of subaortic RUNX1<sup>+</sup> mesenchymal cells has been reported previously,<sup>5,22,24</sup> but their exact identity remains unknown. Therefore, we isolated FACS-mesenchyme (FACS-MES: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>-</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>) cells from both heterozygote and homozygote *Runx1b*<sup>RFP</sup> reporter embryos (Figure 2A; supplemental Figure 5B,C).

In HE, the *Runx1b* isoform precedes the expression of *Gfi1*<sup>21</sup> and both genes are essential for the initiation of EHT.<sup>8,15,21</sup> To illustrate this developmental relationship between RUNX1 and GFI1, we isolated phenotypic Runx1b:RFP<sup>+</sup>Gfi1:GFP<sup>-</sup> E10.5 AGM HE


(CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>Gfi1:GFP<sup>-</sup>) from *Runx1b*<sup>RFP</sup>/*Gfi1*<sup>GFP</sup> reporter embryos. Following 24 hours of aggregation culture, the Runx1b:RFP<sup>+</sup>Gfi1:GFP<sup>-</sup> HE gave rise to Runx1b:RFP<sup>+</sup>Gfi1:GFP<sup>+</sup> HE and progenitors (supplemental Figure 6).

UMAP visualization of the sequenced FACS populations (Figure 2B) demonstrated that FACS-ENDO populations from different reporter models (FACS-ENDO<sup>Runx1b-het</sup>, FACS-ENDO<sup>Runx1b-KO</sup>, and FACS-ENDO<sup>Gfi1-het</sup>) clustered together, indicating that batch effects were negligible (supplemental Figure 7A). We identified 3 distinct groups of robust clusters (Figure 2C), which we annotated based on marker gene expression and correlation to the FACS populations (Figure 2C-E; supplemental Figures 7 and 8; supplemental Table 4): 3 endothelial clusters (C1:ENDO-VE, C2:ENDO-unclassified, C3:ENDO-AE), 5 clusters encompassing the EHT-continuum (C4-C6:HE, C7:EHT, C8:IAHC), and 2 mesenchymal (MES) clusters (C9:MES-PDGFRa, C10:MES-SMA). Surprisingly some FACS-HE<sup>Runx1b-het</sup>, with lower levels of CDH5, were assigned to C10:MES-SMA (supplemental Figure 9A). Subsequent immunofluorescence and FACS analyses confirmed that in the E10.5 AGM, a small proportion of the smooth muscle cell population is CDH5<sup>+</sup> (supplemental Figure 9B-F).

Zhu et al have recently described an AGM pre-HE population.<sup>34</sup> To determine if pre-HE is present in our dataset, we investigated to what extent our data correlate with the Zhu study (supplemental Figure 10). Overall, the 3 groups of clusters (Endo:C1-C3, HE-IAHC:C4-C8, MES:C9-10) correlated well with the equivalent groups in the Zhu data set. However, within the HE-IAHC group (C4-C8), there were notable differences with regard to cluster classification. We found that the HE cluster identified by Zhu et al is highly similar to C7:EHT in our dataset. The majority of cells in C7 express high amounts of *CD41* (*Itga2b*), *CD61* (*Itgb3*), *Kit*, and *Gfi1b* while also demonstrating a marked reduction (vs C4-C6) in the expression levels of endothelial genes including *Kdr*, *Pecam1*, *Tmem100*, and *Cdh5* (supplemental Figure 8C). A substantial fraction of C7 originates from FACS-EHT<sup>Gfi1-het</sup> (70%) and FACS-IAHC<sup>Gfi1-het</sup> (19%) (supplemental Figure 8B). As such, the cells in C7 are no longer embedded in the endothelial lining of the AGM and are actively undergoing EHT and cannot be classified as HE. C6 mainly consists of FACS-HE<sup>Gfi1</sup> cell (81%; supplemental Figure 8B), displays low/absent expression of *Itga2b*, *Itgb3*, *Kit*, and *Gfi1b* and expresses high levels of endothelial transcripts (supplemental Figure 8C). This phenotype corresponds to HE cells that are embedded in the DA endothelial lining and do not yet show morphological changes indicative of EHT. Therefore, we designated the clusters in the EHT continuum as follows: C4:pre-HE *Runx1*<sup>KO</sup> (pre-HE<sup>KO</sup>), C5:pre-HE, C6:HE, C7:EHT, and C8:IAHC (Figure 2C).

Surprisingly, *Runx1* transcripts were only detected in a small fraction (7.4%) of the FACS-HE<sup>Runx1b-het</sup> cells in C5:pre-HE (supplemental Figure 11A), suggesting a poor correlation between

**Figure 1 (continued)** isolated from the E10.5 and E11.5 DA. FACS populations (left) and in silico clustering (right). (C) Top: Distribution of FACS-isolated populations in each cluster with background shaded according to the embryonic day of the samples. Bottom: Heat map illustrating the hematopoietic and endothelial gene expression profile of each cluster. Genes were clustered based on Pearson correlation, whereas the cells were grouped according to the clustering results. (D) Gene ontology (GO) analysis of genes upregulated in E11.5 FACS-HE<sup>Gfi1-het</sup> compared with E10.5 FACS-HE<sup>Gfi1-het</sup>. (E) Violin plot combined with box plot showing the normalized expression (log counts) of venous (*Aplnr*), arterial (*Fbln5*), and arterial fate promoting (*Notch1*, *Jag1*, *Sox7*, *Sox17*) genes in indicated populations. The shaded background behind the plot indicates the embryonic day origin of the cells. Medians are shown as a solid black line; gray boxes indicate the upper (75%) and lower (25%) percentile. \**P* < .05, \*\**P* < .01, \*\*\**P* < .001 (2-tailed Student t test). NS, not significant.



**Figure 2. A single-cell resolution atlas of E10.5 AGM.** (A) Schematic representation of FACS populations based on *Runx1b*<sup>RFP</sup>, *Gfi1*<sup>tomato</sup>/*Gfi1b*<sup>GFP</sup>, and *Gfi1*<sup>GFP</sup>/*Gfi1b*<sup>GFP</sup> reporter mouse models. Cells isolated from *Runx1b*<sup>RFP</sup> reporter include FACS-MES<sup>Runx1b-het</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>+</sup>Runx1b:RFP<sup>+</sup>),

Runx1b:RFP reporter and *Runx1* expression and/or a low scRNA-seq *Runx1* detection sensitivity. Immunofluorescent staining of E10.5 *Runx1b*<sup>RFP</sup> AGM sections for RFP and RUNX1 proteins demonstrated a good correlation in the DA (78% of RFP<sup>+</sup> are RUNX1<sup>+</sup>, 81% of RUNX1<sup>+</sup> are RFP<sup>+</sup>; supplemental Figure 11B,C). This indicates that even the full-length sequencing protocol is not sensitive enough to robustly detect low levels of *Runx1* transcripts in the C5:pre-HE population.

### Trajectory analysis of E10.5 EHT uncovers a detailed HE maturation continuum

To identify changes associated with HE differentiation, we focused on clusters C4 through C8, which cover the continuum from pre-HE cells to IAHC. Unlike the *Runx1b*<sup>KO</sup> pre-HE, which clustered separately from their *Runx1b*<sup>het</sup> counterparts (Figure 2B,C; C4:pre-HE<sup>KO</sup>, C5:pre-HE), both the *Gfi1/1b*<sup>KO</sup> and *Gfi1*<sup>het</sup> HE populated the same cluster (Figure 2B,C; C6:HE). Therefore, we subdivided cluster C6 based on the *Gfi1* genotype (C6:HE<sup>KO</sup> and C6:HE) before inferring a developmental trajectory (Figure 3A,B). As expected, endothelial transcripts (*Cdh5*, *Kdr*, *Pecam1*) decreased across the developmental trajectory, whereas hematopoietic transcripts (*Gfi1*, *Mpo*, *Gfi1b*) increased (supplemental Figure 12A). Although the pre-HE clusters (C4 and C5) did not cluster together with the endothelial clusters (C1-C3), they still displayed robust arterial gene expression (*Vwf*, *Bmx*, *Hey2*, and *Jag1*) (supplemental Figure 8C). This is expected because the cells in these clusters do not express significant amounts of *Gfi1*, which is instrumental for initiating the downregulation of the endothelial program.<sup>20,21</sup> In both *Runx1*<sup>KO</sup> and *Gfi1/1b*<sup>KO</sup> mice, IAHC are absent<sup>21,22,59</sup> and development arrests before EHT (C7). This is illustrated by the absence of KIT<sup>+</sup> cells in E10.5 AGMs (supplemental Figure 12B,C). Interestingly, the KO clusters (C4:pre-HE<sup>KO</sup>, C6:HE<sup>KO</sup>) sit at different points in the pseudotime trajectory, illustrating that they are arrested at different pre-EHT stages. C4:pre-HE<sup>KO</sup> sits within the EHT continuum, whereas C6:HE<sup>KO</sup> seems to divert away from this trajectory (Figure 3A; supplemental Figure 12D). Altogether, these data show that we captured a detailed HE differentiation trajectory.

### Pre-HSC-like gene signatures can be detected in HE

AGM IAHC contain cells with different differentiation signatures such as myeloid cells, pre-HSCs, and HSCs.<sup>11,32,34,60-62</sup> To determine if a similar heterogeneity is present in HE, we screened the EHT continuum (C4-C8) for the presence of the following gene signatures: arterial,<sup>63</sup> erythroid-myeloid progenitors,<sup>64</sup> lymphoid-myeloid progenitors,<sup>65</sup> pre-HSCs,<sup>31</sup> and HSCs<sup>66</sup> (supplemental Figure 13; supplemental Table 5). Within C8:IAHC, positive cells for all 4 hematopoietic signatures could be detected in a mutually exclusive way. Pre-HSC and HSC signatures could be

detected in C7:EHT, whereas in C6:HE, only the pre-HSC signature could be discerned.

### Cell-cycle status differentiates pre-HE from HE


Next, we sought to identify what distinguishes pre-HE from HE. To characterize changes relevant to normal HE progression, we excluded *Runx1*<sup>KO</sup> and *Gfi1/1b*<sup>KO</sup> cells and examined transcriptional differences between C5:pre-HE and C6:HE. We identified 2272 DEGs with the majority upregulated in C6:HE (Figure 3C; supplemental Table 6). Pathways associated with AE identity were enriched in C5:pre-HE. These included integrin and cadherin signaling, which are important for cell-cell and cell-matrix interactions,<sup>67,68</sup> and Notch and Wnt signaling, which both need to be downregulated to drive EHT forward.<sup>69-71</sup> Strikingly, the upregulated genes in C6:HE were dominated by cell cycle-related pathways. We, therefore, analyzed the cell-cycle status of all clusters (C4-C8), including the KO cells. In line with previous findings, most C8:IAHC cells were in the G2/M or S phase<sup>72</sup> (Figure 3D; supplemental Figure 13C). However, an increase in cycling cells could already be detected in C6:HE. Interestingly, C6:HE<sup>KO</sup> phenocopies its C6:HE heterozygous counterpart with regard to cell-cycle status (Figure 3D). We confirmed these results by immunofluorescence analysis of CCNB1 (marking G2/M)<sup>73</sup> and Ki67 (marking G1, S, G2/M)<sup>74</sup> in E10.5 *Gfi1*-reporter embryos. CD31<sup>+</sup>Gfi1:Tomato<sup>+</sup> expressed higher levels of CCNB1 and Ki67 relative to CD31<sup>+</sup>Gfi1:Tomato<sup>-</sup> AE in the DA (Figure 3E-H). Similarly, we observed increased entry into the cell cycle at the late stages of HE differentiation upon *in vitro* hematopoietic differentiation of fluorescent, ubiquitination-based cell-cycle indicator mouse embryonic stem cells<sup>75</sup> (supplemental Figure 13D). Together, these results indicate that as HE cells get closer to EHT, they start downregulating their arterial identity while entering the cell cycle. The latter does not appear to rely on GFI1.

### ACE: a novel HE cell-surface enrichment marker

Currently, HE isolation is heavily reliant on transgenic reporter models.<sup>21,23,33,35,76-78</sup> To identify HE cell-surface markers, for use in a wild-type context, we compared each cluster along the EHT trajectory to C3:ENDO-AE (supplemental Table 7). The resulting list of surface markers was screened for no/low expression in C1:ENDO-VE and antibody availability.

*Neur13* expression was observed in C6:HE-C8:IAHC, whereas *CD27* and *Flt3/CD135* were highly expressed in C8:IAHC. *Neur13* is a recently identified HE/pre-HSC marker,<sup>33</sup> *CD27* has been shown to mark pre-HSC/HSC,<sup>79</sup> and *Flt3* marks early hematopoietic progenitors.<sup>80,81</sup> *CD44*, *Procr/CD201*, and *Ace/CD143* were highly expressed in the pre-HE and HE populations (Figure 4A). Both *CD44* and *Procr* were expressed throughout the AGM CDH5<sup>+</sup> population from C1:ENDO-VE to C8:IAHC. In contrast, *Ace* was mainly restricted to the pre-HE to HE

**Figure 2 (continued)** FACS-ENDO<sup>Runx1b-het</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>), and FACS-HE<sup>Runx1b-het</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>). Cells isolated from *Runx1b*<sup>KO</sup> include FACS-MES<sup>Runx1b-KO</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>), FACS-ENDO<sup>Runx1b-KO</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>), and FACS-HE<sup>Runx1b-KO</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Runx1b:RFP<sup>+</sup>). Cells isolated from *Gfi1*<sup>tomato</sup>/*Gfi1b*<sup>GFP</sup> are as described in Figure 1A. FACS-HE<sup>Gfi1/1b-KO</sup> (CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>Gfi1:GFP<sup>+</sup>) was isolated from *Gfi1*<sup>GFP</sup>/*Gfi1b*<sup>GFP</sup> reporter. (B) Uniform Manifold Approximation and Projection (UMAP) plots showing all cells (left), heterozygote cells only (middle), and KO cells only (right). Cells are colored by FACS populations. (C) Two-dimensional UMAP with cells colored by *in silico* clustering. (D) Expression of venous endothelial (*Nrp2*), arterial endothelial (*Gja5*, *Vwf*), hematopoietic (*Gfi1b*), and mesenchymal (*Bmp4*, *Dlk1*) genes in the UMAP plot. (E) Violin plots combined with box and whisker plots showing the normalized expression (logcounts) of indicated genes in each cluster. The color coding is identical to panel C. Medians are shown as a solid black line; boxes indicate the upper (75%) and lower (25%) percentile; whiskers indicate  $\pm 1.5$  times the interquartile range (IQR). Outliers (values  $>$  or  $<$  1.5 IQR) are shown as dots. AE, arterial endothelial; EHT, endothelial-to-hematopoietic transition; ENDO, endothelial; HE, hemogenic endothelium; IAHC, intra-aortic hematopoietic clusters; UC, unclassified; VE, venous endothelial.



**Figure 3. Cell-cycle progression is initiated before IAHC formation.** (A) Force directed graph (FDG) visualization of all cells in the EHT continuum. (B) Density plot showing the distribution of cells across inferred trajectory (pseudotime: scaled from 0 to 100). (C) Left: Heatmap illustrating the differentially expressed genes (DEGs)

continuum (C4-C6), in particular to the pre-HE clusters (C4-C5). The *Runx1b*<sup>KO</sup> (C4:pre-HE<sup>KO</sup>) and *Gfi1/1b*<sup>KO</sup> HE (C6:HE<sup>KO</sup>) showed comparable *Ace* expression levels to their EHT competent counterparts (C5:pre-HE and C6:HE). Unlike CD44<sup>82</sup> and PROCR,<sup>31</sup> ACE has not been previously identified as a murine HE marker; therefore, we analyzed it further. Immunofluorescence for ACE on E10.5 AGM sections correlated well with the scRNA-seq data. ACE expression was exclusively seen in CD31<sup>+</sup> DA cells within the AGM (Figure 4B), including the RUNX1<sup>+</sup> and *Gfi1:Tomato*<sup>+</sup> subsets (Figure 4C; supplemental Figure 14A) embedded within the CD31<sup>+</sup> lining (likely HE). In contrast, CD31<sup>+</sup> cells budding into the DA lumen (likely IAHC) showed reduced/absent ACE staining. Overall, we found that on average 27% of the CD31<sup>+</sup> cells within the E10.5 DA lining coexpressed ACE (Figure 4B). We observed a similar ACE expression pattern in the E10.5 vitelline artery (supplemental Figure 14B), another known site of hematopoietic emergence.<sup>13,83</sup> Next, we assessed the ability of ACE to enrich for *Gfi1:Tomato*<sup>+</sup> AGM HE cells from the *Gfi1*<sup>Tomato</sup>/*Gfi1b*<sup>GFP</sup> transgenic reporter. In line with the scRNA-seq, ACE marked a smaller subpopulation of the LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup> cells compared with CD44 (supplemental Figure 15A-C). Consequently, gating on LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup>ACE<sup>+</sup> cells resulted in an improved enrichment of *Gfi1:GFP*<sup>+</sup> cells compared with both LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup> and LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup>CD44<sup>+</sup> gating (Figure 4D).

To confirm hemogenic activity within LIN<sup>-</sup>CDH5<sup>+</sup>ACE<sup>+</sup> AGM cells, we first performed ACE depletion assays. LIN<sup>-</sup>(CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>) E10.5 AGMs depleted, or not, of CDH5<sup>+</sup>ACE<sup>+</sup> cells were matured as aggregates before being analyzed in CFU assays (Figure 4E). Robust colony formation was observed from the majority of the LIN<sup>-</sup> aggregates (n = 13 AGMs). In contrast, LIN<sup>-</sup>ACE<sup>-</sup> aggregates (n = 14 AGMs) did not contain CFU activity. Next, we FACS isolated LIN<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>ACE<sup>+</sup> and LIN<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>ACE<sup>-</sup> cells from E10.5 AGMs and cocultured them (100 cells/well) on vascular niche cells.<sup>44,45</sup> Hematopoietic activity was only observed in the ACE<sup>+</sup> group (n = 4; Figure 4F). Finally, we performed scRNA-seq on FACS E10.5 AGM ACE<sup>+</sup> (FACS-preHE<sup>ACE-SP</sup>: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>ACE<sup>+</sup>*Gfi1:GFP*<sup>-</sup> and FACS-HE<sup>ACE-DP</sup>: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>ACE<sup>+</sup>*Gfi1:GFP*<sup>+</sup>), and ACE<sup>-</sup> (FACS-ENDO<sup>ACE-NEG</sup>: CD41<sup>-</sup>CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>+</sup>KIT<sup>-</sup>ACE<sup>-</sup>*Gfi1:GFP*<sup>-</sup>) cells and projected the data on our existing E10.5 EHT UMAP (Figure 4G; supplemental Figure 15D,E). A total of 78.5% of all ACE<sup>+</sup> sorted cells (n = 121, FACS-preHE<sup>ACE-SP</sup> and FACS-HE<sup>ACE-DP</sup>) clustered within the HE continuum (56.2% in C5:pre-HE, 22.3% in C6:HE). The remaining 21.5% populated C1 (1.7%), C2-C3 (11.5%), and C7-C8 (8.3%). FACS-preHE<sup>ACE-SP</sup> predominantly clustered within C5:pre-HE (64.3%), whereas FACS-HE<sup>ACE-DP</sup> mainly clustered within C6:HE (45.9%; Figure 4H). Altogether these results indicate that ACE can be used to enrich functional pre-HE and HE in lieu of transgenic reporters. Notably, *Ace* was not detected in our previous 3'-based scRNA-seq study,<sup>32</sup> nor in the recent Zhu et al study<sup>34</sup>

(supplemental Figure 15F), further highlighting the higher gene detection rate in our study.

## RUNX1<sup>+</sup> mesenchymal cells support AGM hematopoiesis

Currently, little is known about the subpopulation of mesenchymal cells in the AGM that express the hematopoietic master regulator *Runx1*. To determine their potential role in hematopoiesis, we performed aggregation cultures and CFU assays with FACS CD45<sup>-</sup>TER119<sup>-</sup>CDH5<sup>-</sup> depleted, or not, of *Runx1b:RFP*<sup>+</sup> E10.5 AGM cells (Figure 5A). Depletion of *Runx1b:RFP*<sup>+</sup> mesenchymal cells resulted in a more than five-fold decrease in CFU potential (n = 7). These results indicate that *Runx1b:RFP*<sup>+</sup> mesenchyme positively influences hematopoiesis.

## RUNX1<sup>+</sup> subaortic cells contribute to the smooth muscle lineage and PDGFRa mesenchyme


The scRNA-seq analysis revealed 2 distinct *Runx1b:RFP*<sup>+</sup> mesenchymal clusters (C9:MES-PDGFRa, C10:MES-SMA; Figure 2C-E), which contributed equally to the total *Runx1*<sup>+</sup> mesenchymal population (supplemental Figure 16A). Upon *Runx1b* knockout (KO), the distribution shifted toward C10 (supplemental Figure 16A). Index FACS and scRNA-seq data revealed that in C9:MES-PDGFRa, the *Runx1b*<sup>RFP</sup> locus is less active than in C10:MES-SMA (supplemental Figure 16B).

DEG analysis of all the upregulated genes in the mesenchymal clusters in comparison with the other clusters (C9-C10 vs C1-C8) indicated that most of these genes were either specifically upregulated in C10 (48%) or upregulated in both C9:MES-PDGFRa and C10:MES-SMA (49%) (supplemental Figure 16C; supplemental Table 8). Enrichment analysis of the latter indicated a general mesenchymal identity, whereas analyses of the C10:MES-SMA upregulated genes suggested a smooth muscle cell identity (supplemental Figure 16D; supplemental Table 9). Only a small number of genes (n = 13), including *Pdgfra*, was upregulated specifically in C9:MES-PDGFRa.

The smooth muscle cell identity of C10 was further supported by gene set enrichment analysis (GSEA), showing a strong enrichment for "actin" and "smooth muscle" related pathways with high expression of *Actg2*, *Acta2*, *Cnn1*, and *Mcam/CD146* (Figure 5B; supplemental Figure 16E,F). SMA (Figure 5C) and MCAM (supplemental Figure 16G) immunofluorescence showed that RUNX1<sup>+</sup> smooth muscle cells were predominantly detected on the ventral side of the DA below the CD31<sup>+</sup> endothelium. We also observed a thickening of the SMA and RFP layer around the DA in *Runx1b*<sup>KO</sup> sections (supplemental Figure 17A,B). GSEA revealed ribosomal transcripts to be enriched in C10<sup>Runx1b-KO</sup> vs C10<sup>Runx1b-het</sup> (supplemental Figure 17C). Subsequent screening of publicly available RUNX1 binding data<sup>84-88</sup> suggests that at least some of these ribosomal genes (11/66) can be directly bound by RUNX1 (supplemental Table 10), as previously reported.<sup>89-91</sup> Unbiased clustering on C10 revealed 2 subclusters (C10-A and C10-B; supplemental Figure 17D). C10-

**Figure 3 (continued)** between the heterozygous cells in C5:pre-HE and C6:HE based on 1.4 Log<sub>2</sub> fold change and false discovery rate <0.05. Right: Panther pathway analysis of the upregulated genes in each cluster. (D) Distribution of the cell-cycle phase in indicated clusters. (E,G) A magnified image of immunofluorescent staining on frozen E10.5 dorsal aorta sections for CD31 (red), *Gfi1:Tomato* (cyan), and CCNB1 (E, yellow) or Kl67 (G, yellow). (F,H) Quantification of CCNB1 (F) and Kl67 (H) signal intensity in CD31 endothelial cells lining the entire dorsal aorta. Individual cells and medians are shown; gray boxes indicate the upper (75%) and lower (25%) percentile; whiskers indicate ±1.5 times the interquartile range (IQR). Two-tailed t test. \*P < .05, \*\*\*P < .001.





**Figure 4. ACE (CD143) is an HE enrichment marker.** (A) Violin plots showing the expression of shortlisted cell surface markers. *Cd31* expression is shown for reference. The mean expression is indicated by the horizontal black line. The percentage of cells with non-zero expression (read count >0) is shown above each plot.

A consisted of both *Runx1b*<sup>het</sup> (41%) and *Runx1b*<sup>KO</sup> (59%) cells, whereas C10-B predominantly harbored *Runx1b*<sup>het</sup> cells (94%). Interestingly, most of the *Runx1b*<sup>KO</sup> cells (92%) are contained in C10-A. GSEA demonstrates enrichment of gene sets related to proliferation (MYC targets, mTOR signaling) in C10-A, whereas gene sets related to muscle cell identity/physiology are enriched in C10-B (supplemental Figure 17E). Hence, the C10<sup>Runx1b-KO</sup> cells appear to preferentially possess a gene expression profile compatible with an increased proliferation capacity. This could explain the higher number of subaortic RUNX1<sup>+</sup> cells observed in *Runx1*-deficient embryos.

C9:MES-PDGFRa did not present a specific identity apart from the absence of smooth muscle cell characteristics (Figure 5B; supplemental Figure 16D). Spatially, the cells in C9:MES-PDGFRa resided below the smooth muscle layer and, like C10:MES-SMA, the C9:RUNX1<sup>+</sup>PDGFRA<sup>+</sup> cells were predominantly detected on the ventral side of the DA (Figure 5C-E). DEG analysis between C9<sup>Runx1b-KO</sup> and C9<sup>Runx1b-het</sup> did not identify significantly enriched gene sets. This was reflected in clustering analysis that revealed no obvious subclusters in C9 (supplemental Figure 17F). However, we did observe that *Ptn* (Pleiotrophin) expression was not only significantly upregulated in C9 as a whole, but the highest expression was seen in C9<sup>Runx1b-het</sup> (Figure 5F). RUNX1 binding analysis using published data<sup>84-88</sup> revealed the *Ptn* locus as a potential direct RUNX1 target (supplemental Table 11). PTN has been implicated in HSC self-renewal and retention in the bone marrow vascular niche.<sup>92</sup> To determine if PTN can play a role during AGM hematopoietic ontogeny, we performed *ptn* knockdown experiments in developing zebrafish. *ptn* knockdown resulted in a substantial decrease of emerging hematopoietic cells (*kdr1*<sup>+</sup>*cd41*<sup>+</sup>) in the DA at the 35 hours post fertilization (hpf) stage followed by a significant reduction of hematopoietic stem and progenitor cells (HSPCs) in the caudal hematopoietic tissue at 55 hpf (Figure 5G,H; supplemental Figure 18). This indicates that PTN can play a role in the DA EHT. Together, these results reveal the identity of the RUNX1<sup>+</sup> subaortic cells as smooth muscle cells and PDGFRa mesenchyme.

## Discussion

Unraveling the molecular programs driving HSC formation during embryogenesis would be invaluable for developing protocols supporting in vitro generation and amplification of HSC to treat blood malignancies.<sup>1,2</sup> Here, we present a high-resolution scRNA-seq dataset that encompasses sequential stages of blood formation in the mouse AGM region at the time of HSC formation. We focused on in-depth profiling of HE development and


RUNX1B mesenchyme by analyzing FACS populations from *Runx1* and *Gfi1/1b* reporter mouse models.

By combining full-length scRNA-seq with the functional and phenotypic characterization of the sequenced FACS populations, we were able to precisely stage E10.5 pre-HE and HE populations within the EHT continuum. These assignments differ from those previously published.<sup>34</sup> Our data indicate that cells previously labeled as HE are more mature EHT cells and that cells previously labeled as pre-HE consist of both pre-HE and HE. The reassignment of HE cells to cells undergoing EHT suggests that the previously described differentiation bottleneck<sup>34</sup> between pre-HE and HE could actually be a threshold between HE and the initiation of hematopoietic commitment (EHT). Our transcriptomic analyses also demonstrated that E11.5 HE has a strongly reduced hemogenic profile and is consequently less equipped to clear a potential bottleneck between HE and EHT. This unifies the seemingly contradictory observations that the AGM HE activity peaks around E10.5,<sup>93</sup> whereas the frequency of phenotypic hemogenic endothelium (LIN<sup>-</sup>CDH5<sup>+</sup>Gfi1:Tomato<sup>+</sup>) is similar in the E10.5 and E11.5 AGM.<sup>21</sup>

We also found cell-cycle status to be a distinguishing feature between pre-HE and HE and identified ACE as an enrichment marker for both populations. We uncovered that *Ace* transcript expression is mainly restricted to pre-HE/HE and compares favorably to the previously identified HE markers *CD44* and *Procr* whose expression is detected in a wider range of AGM CDH5<sup>+</sup> cells (endothelial to IAHC). In humans, ACE marks prehematopoietic mesoderm, aortic endothelial cells, and HSPCs.<sup>94,95</sup> In the E10.5 mouse AGM, we observed ACE expression exclusively in the endothelial lining of the DA and vitelline artery, which contain pre-HE and HE, whereas no robust ACE expression was observed anywhere else including in the more committed hematopoietic cell in IAHC.

The exclusive expression of ACE in the DA and vitelline artery lining suggests that it may contribute to a unique microenvironment promoting hematopoiesis. ACE converts angiotensin-1 into angiotensin-2, which in turn activates angiotensin-2 receptors (AT1, AT2).<sup>96</sup> Two recent reports<sup>97,98</sup> have implicated the endothelin-renin-angiotensin system (which includes ACE) in AGM hematopoiesis. In human and mouse, *Atgr1* (coding for AT1) expression has been detected in subaortic DA cells.<sup>97,98</sup> In line with this, we observed *Atgr1* expression in the RUNX1<sup>+</sup> mesenchymal population, particularly in the smooth muscle fraction (C10:SMA; supplemental Figure 19). Julien et al<sup>98</sup> have recently shown that angiotensin-2 mediated activation of AT1 can promote the emergence of hematopoietic progenitors in

**Figure 4 (continued)** (B) Representative immunofluorescence (IF) staining of formalin-fixed paraffin-embedded (FFPE) sections of E10.5 embryo sections for CD31 (red) and ACE (gray). D, dorsal; DA, dorsal aorta; NT, neural tube; V, ventral. (C) Left: IF staining of E10.5 AGM FFPE sections in panel B. CD31 (red), RUNX1 (green), and ACE (gray). Example IAHC cells are indicated with magenta arrow. White arrows indicate example RUNX1<sup>+</sup> cells in the lining of the aorta. Right: Percentage of ACE<sup>+</sup> cells in CD31<sup>+</sup> E10.5 DA. (D) FACS plots showing the enrichment of E10.5 HE with CDH5<sup>+</sup> alone (left), CDH5 and CD44 (middle), CDH5 and ACE (right). (E) Experimental design of hanging drop reaggregation AGM cultures with LIN (CD41<sup>+</sup>CD45<sup>+</sup>TER119<sup>+</sup>) depleted or LIN and ACE (LIN<sup>-</sup>CDH5<sup>+</sup>ACE<sup>+</sup>) depleted cells. CFU assays were performed after 4 days of culture. The numbers of replicates are indicated at the bottom of each column. Two-tailed Student t test was used to assess statistical significance. Error bars represent SEM. \*\**P* < .01. (F) Numbers of wells with proliferating cells following 10 days of coculture of FACS sorted LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup>ACE<sup>+</sup> or LIN<sup>-</sup>KIT<sup>-</sup>CDH5<sup>+</sup>ACE<sup>-</sup> cells (100 cells/well) on vascular niche cells. Exp, experiment. (G) UMAP computed from integrating cells from cluster C1-C8 (excluding KO cells and KO clusters) with scRNA-seq data obtained from sorted ACE<sup>+</sup> and ACE<sup>-</sup> E10.5 AGM cells. Left: UMAP representation of the previously determined in silico clusters C1-C8 from Figure 2C (excluding KO cells and KO clusters). Right: scRNA-seq data obtained from sequencing ACE<sup>+</sup> and ACE<sup>-</sup> cells. (H) Heatmap displaying the percentage of cells from the ACE scRNA-seq data mapped to the in silico clusters based on k-nearest-neighbor classifier approach. AE, arterial endothelial; EHT, endothelial-to-hematopoietic transition; ENDO, endothelial; HE, hemogenic endothelium; IAHC, intra-aortic hematopoietic clusters; UC, unclassified; VE, venous endothelial.



**Figure 5. Identification of 2 different RUNX1 subpopulations in the subaortic mesenchyme.** (A) Left: experimental design of E10.5 AGM hanging drop reaggregation cultures with LIN (CD45<sup>+</sup>TER119<sup>+</sup>) depleted, or LIN and MES (LIN<sup>-</sup>CDH5<sup>+</sup>Runx1b:RFP<sup>+</sup>) depleted cells. CFU assays were performed after 4 days of culture. Right: Bar graph depicting average colony number ± SEM. The number of assayed AGMs are indicated in the bars. \*\*\**P* < .001 (2-tailed Student *t* test). (B) Heatmap illustrating the top differentially expressed genes between the C9:MES-PDGFRa and C10:MES-SMA. Genes are clustered based on Pearson correlation and cells are grouped based on the in silico clusters. Genes coding for secreted proteins are highlighted in bold. (C-D) Top left: immunofluorescence (IF) staining of formalin-fixed paraffin-embedded (FFPE) E10.5 AGM sections for CD31 (red), RUNX1 (green) and SMA (yellow, C), or PDGFRA (gray, D). DA, dorsal aorta. Bottom left: ×100 magnification of the boxed region in the top panel. Right: quantification of SMA (C) and PDGFRA (D) positive cells within the top field of view. (E) Density plot depicting the distance of RUNX1<sup>+</sup>SMA<sup>+</sup> and RUNX1<sup>+</sup>PDGFRA<sup>+</sup> cells in relation to the endothelial (CD31<sup>+</sup>) cells lining the DA. (F) Violin plot combined with box plot showing the normalized expression (logcounts) of Pleiotrophin (*Ptn*) in Runx1 heterozygous (HET, *Runx1b*<sup>RFP<sup>+/WT</sup>) or Runx1 knockout (KO, *Runx1b*<sup>RFP<sup>+/RFP</sup>) C9 and C10 clusters. Medians are shown as a solid black line, gray boxes indicate the upper (75%) and lower (25%) percentile. (G) Representative 35 hpf confocal images of no morpholino control and *ptn* morpholino treated (100 μM) *Tg(cd41:eGFP)/kdr1:caax:mCherry* zebrafish embryos. Emerging HSPC (*cd41*, *kdr* double-positive cells) in the 35 hpf AGM are indicated with white arrows. (H) Quantification of the emerging HSPC (*kdr1*<sup>+</sup>*cd41*<sup>+</sup>) in the 35 hpf AGM of embryos treated with no morpholino (no MO), control scrambled morpholino (100 μM), and *ptn* morpholino (10 and 100 μM). Individual fish (dots) and mean ± SEM are shown. \**P* < .05, \*\**P* < .01 (2-tailed, unpaired Student *t* test). NS, not significant; SEM, standard error of the mean.</sup></sup>

mouse para-aortic splanchnopleure cultures. Therefore, angiotensin-2 mediated signaling through AT1 on C10:SMA cells could, partially, explain our observation that Runx1b:RFP<sup>+</sup> mesenchyme can support hematopoietic activity.

The PDGFRa<sup>+</sup> mesenchymal (C9:MES-PDGFRa) fraction of the Runx1b:RFP<sup>+</sup> mesenchyme can also play a role in stimulating hematopoiesis. We found that PTN, a secreted growth factor that plays a role in adult hematopoiesis,<sup>92</sup> is expressed by Runx1b:RFP<sup>+</sup>PDGFRa<sup>+</sup> mesenchymal cells in a RUNX1-dependent way. Our observation that *ptn* knockdown, in developing zebrafish, significantly inhibits HSPC emergence in the AGM and suggests that local mesenchymal PTN production in the AGM plays a role in the EHT process.

Finally, our findings were greatly facilitated by employing high coverage full-length scRNA-seq on defined cell populations. Phenotypic knowledge of the sequenced populations regarding protein expression and transcriptionally active loci (as determined using reporter models) provided an invaluable extra layer of information to aid interpretation of the scRNA-seq data. Overall, our data constitute a comprehensive atlas of EHT, which can be interrogated by the community to further our understanding of this process.

## Acknowledgments

The authors thank the following facilities of the Cancer Research UK Manchester Institute for technical support: Advanced Imaging, Biological Resources Unit, Flow Cytometry, and the Molecular Biology Core Facility.

The study was supported by Cancer Research UK, C5759/A20971 (G.L.). Research in the Kouskoff laboratory is supported by the Medical Research Council (MR/P000673/1, MR/T000384/1) and the Biotechnology and Biological Sciences Research Council (BB/R007209/1).

## REFERENCES

- Slukvin II. Generating human hematopoietic stem cells in vitro -exploring endothelial to hematopoietic transition as a portal for stemness acquisition. *FEBS Lett.* 2016; 590(22):4126-4143.
- Wilkinson AC, Igarashi KJ, Nakauchi H. Haematopoietic stem cell self-renewal in vivo and ex vivo. *Nat Rev Genet.* 2020;21(9): 541-554.
- Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell.* 1996;86(6):897-906.
- Cumano A, Ferraz JC, Klaine M, Di Santo JP, Godin I. Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. *Immunity.* 2001;15(3):477-485.
- North TE, de Bruijn MFTR, Stacy T, et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the mid-gestation mouse embryo. *Immunity.* 2002;16(5):661-672.
- Jaffredo T, Gautier R, Eichmann A, Dieterlen-Lièvre F. Intraaortic hemopoietic cells are derived from endothelial cells

during ontogeny. *Development.* 1998; 125(22):4575-4583.

- Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. *Nature.* 2010; 464(7285):112-115.
- Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. *Nature.* 2009;457(7231):892-895.
- Boisset J-C, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. *Nature.* 2010;464(7285):116-120.
- Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D. Haematopoietic stem cells derive directly from aortic endothelium during development. *Nature.* 2010; 464(7285):108-111.
- Boisset J-C, Clapes T, Klaus A, et al. Progressive maturation toward hematopoietic stem cells in the mouse embryo aorta. *Blood.* 2015;125(3):465-469.
- Yokomizo T, Dzierzak E. Three-dimensional cartography of hematopoietic clusters in the

vasculature of whole mouse embryos. *Development.* 2010;137(21):3651-3661.

- de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. *EMBO J.* 2000;19(11):2465-2474.
- Eilken HM, Nishikawa S, Schroeder T. Continuous single-cell imaging of blood generation from haemogenic endothelium. *Nature.* 2009;457(7231):896-900.
- Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. *Nature.* 2009;457(7231): 887-891.
- Lie-A-Ling M, Marinopoulou E, Lilly AJ, et al. Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium. *Development.* 2018;145(5): dev149419.
- Lacaud G, Gore L, Kennedy M, et al. Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. *Blood.* 2002;100(2):458-466.
- Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target

## Authorship

Contribution: M.Z.H.F., W.H.N., M.L., R.T., R.P., and R.M. designed and performed experiments; M.Z.H.F. performed the scRNA-seq data analysis; M.Z.H.F., W.H.N., M.L., and R.T. analyzed the data and wrote the initial draft; M.Z.H.F., W.H.N., and M.L. wrote, reviewed, and generated the figures of the manuscript; I.A. and P.S. provided resources and reagents; N.D.K. and L.F. performed zebrafish experiments; S.M.B. and M.R. supervised bioinformatic analyses; and V.K. and G.L. designed and supervised the research project, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing interests.

ORCID profiles: W.H.N., 0000-0002-6827-3027; M.L., 0000-0003-0194-4313; R.T., 0000-0002-3941-760X; R.M., 0000-0002-2742-6576; I.A., 0000-0003-4353-5876; M.R., 0000-0001-8196-5565; V.K., 0000-0001-9801-4993; G.L., 0000-0002-5630-2417.

Correspondence: Georges Lacaud, Cancer Research UK Manchester Institute, Room 33G71, Aldreley Park, Alderley Edge, Macclesfield SK10 4TG, United Kingdom; e-mail: georges.lacaud@cruk.manchester.ac.uk.

## Footnotes

Submitted 26 June 2020; accepted 19 August 2021; prepublished online on *Blood* First Edition 13 September 2021. DOI 10.1182/blood.2020007885.

\*M.Z.H.F., W.H.N., and M.L. contributed equally to this study.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

- of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell*. 1996;84(2):321-330.
19. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the *Cbfa2* gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc Natl Acad Sci USA*. 1996;93(8):3444-3449.
  20. Lancrin C, Mazan M, Stefanska M, et al. GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment. *Blood*. 2012;120(2):314-322.
  21. Thambyrajah R, Mazan M, Patel R, et al. GFI1 proteins orchestrate the emergence of haematopoietic stem cells through recruitment of LSD1. *Nat Cell Biol*. 2016;18(1):21-32.
  22. North T, Gu TL, Stacy T, et al. *Cbfa2* is required for the formation of intra-aortic hematopoietic clusters. *Development*. 1999;126(11):2563-2575.
  23. Sroczyńska P, Lancrin C, Kouskoff V, Lacaud G. The differential activities of *Runx1* promoters define milestones during embryonic hematopoiesis. *Blood*. 2009;114(26):5279-5289.
  24. Fitch SR, Kapeni C, Tsiotopoulou A, et al. *Gata3* targets *Runx1* in the embryonic haematopoietic stem cell niche. *IUBMB Life*. 2020;72(1):45-52.
  25. Macosko EZ, Basu A, Satija R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. *Cell*. 2015;161(5):1202-1214.
  26. Baron M, Veres A, Wolock SL, et al. A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure. *Cell Syst*. 2016;3(4):346-360.e4.
  27. Ibarra-Soria X, Jawaid W, Pijuan-Sala B, et al. Defining murine organogenesis at single-cell resolution reveals a role for the leukotriene pathway in regulating blood progenitor formation. *Nat Cell Biol*. 2018;20(2):127-134.
  28. Pijuan-Sala B, Griffiths JA, Guibentif C, et al. A single-cell molecular map of mouse gastrulation and early organogenesis. *Nature*. 2019;566(7745):490-495.
  29. Cao J, Spielmann M, Qiu X, et al. The single-cell transcriptional landscape of mammalian organogenesis. *Nature*. 2019;566(7745):496-502.
  30. Swiers G, Baumann C, O'Rourke J, et al. Early dynamic fate changes in haemogenic endothelium characterized at the single-cell level. *Nat Commun*. 2013;4(1):2924.
  31. Zhou F, Li X, Wang W, et al. Tracing haematopoietic stem cell formation at single-cell resolution. *Nature*. 2016;533(7604):487-492.
  32. Baron CS, Kester L, Klaus A, et al. Single-cell transcriptomics reveal the dynamic of haematopoietic stem cell production in the aorta. *Nat Commun*. 2018;9(1):2517.
  33. Hou S, Li Z, Zheng X, et al. Embryonic endothelial evolution towards first hematopoietic stem cells revealed by single-cell transcriptomic and functional analyses. *Cell Res*. 2020;30(5):376-392.
  34. Zhu Q, Gao P, Tober J, et al. Developmental trajectory of pre-hematopoietic stem cell formation from endothelium. *Blood*. 2020;136(7):845-856.
  35. Chen MJ, Lummertz da Rocha E, Cahan P, et al. Transcriptome dynamics of hematopoietic stem cell formation revealed using a combinatorial *Runx1* and *Ly6a* reporter system. *Stem Cell Reports*. 2020;14(5):956-971.
  36. Yücel R, Kosan C, Heyd F, Möröy T. *Gfi1*:green fluorescent protein knock-in mutant reveals differential expression and autoregulation of the growth factor independence 1 (*Gfi1*) gene during lymphocyte development. *J Biol Chem*. 2004;279(39):40906-40917.
  37. Vassen L, Okayama T, Möröy T. *Gfi1b*:green fluorescent protein knock-in mice reveal a dynamic expression pattern of *Gfi1b* during hematopoiesis that is largely complementary to *Gfi1*. *Blood*. 2007;109(6):2356-2364.
  38. Picelli S, Faridani OR, Björklund ÅK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc*. 2014;9(1):171-181.
  39. Picelli S, Björklund ÅK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat Methods*. 2013;10(11):1096-1098.
  40. Lin H-F, Traver D, Zhu H, et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. *Blood*. 2005;106(12):3803-3810.
  41. Chi NC, Shaw RM, De Val S, et al. *Foxn4* directly regulates *tbx2b* expression and atrioventricular canal formation. *Genes Dev*. 2008;22(6):734-739.
  42. Cortes M, Chen MJ, Stachura DL, et al. Developmental vitamin D availability impacts hematopoietic stem cell production. *Cell Rep*. 2016;17(2):458-468.
  43. Sroczyńska P, Lancrin C, Pearson S, Kouskoff V, Lacaud G. In vitro differentiation of mouse embryonic stem cells as a model of early hematopoietic development. *Methods Mol Biol*. 2009;538(16):317-334.
  44. Seandel M, Butler JM, Kobayashi H, et al. Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene. *Proc Natl Acad Sci USA*. 2008;105(49):19288-19293.
  45. Barcia Durán JG, Lis R, Lu TM, Rafii S. In vitro conversion of adult murine endothelial cells to hematopoietic stem cells. *Nat Protoc*. 2018;13(12):2758-2780.
  46. Draper JE, Sroczyńska P, Fadlullah MZH, et al. A novel prospective isolation of murine fetal liver progenitors to study in utero hematopoietic defects. *PLoS Genet*. 2018;14(1):e1007127.
  47. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
  48. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015;31(2):166-169.
  49. McCarthy DJ, Campbell KR, Lun ATL, Wills QF. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics*. 2017;33(8):1179-1186.
  50. Neo WH, Booth CAG, Azzoni E, et al. Cell-extrinsic hematopoietic impact of *Ezh2* inactivation in fetal liver endothelial cells. *Blood*. 2018;131(20):2223-2234.
  51. Mevel R, Steiner I, Mason S, et al. *RUNX1* marks a luminal castration-resistant lineage established at the onset of prostate development. *eLife*. 2020;9:e60225.
  52. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. *Sci Rep*. 2017;7(1):16878.
  53. McInnes L, Healy J. UMAP: Uniform Manifold Approximation and Projection for dimension reduction. arXiv. 2018;1802.03426[stat.ML].
  54. Gama-Norton L, Ferrando E, Ruiz-Herguido C, et al. Notch signal strength controls cell fate in the haemogenic endothelium [published correction appears in *Nat Commun*. 2016;7:10978]. *Nat Commun*. 2015;6(1):8510-8512.
  55. Corada M, Orsenigo F, Morini MF, et al. *Sox17* is indispensable for acquisition and maintenance of arterial identity. *Nat Commun*. 2013;4(1):2609-2614.
  56. Chiang IK-N, Fritzsche M, Pichol-Thievend C, et al. *SoxF* factors induce *Notch1* expression via direct transcriptional regulation during early arterial development. *Development*. 2017;144(14):2629-2639.
  57. Nakamura T, Ruiz-Lozano P, Lindner V, et al. DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. *J Biol Chem*. 1999;274(32):22476-22483.
  58. Yanagisawa H, Davis EC, Starcher BC, et al. *Fibulin-5* is an elastin-binding protein essential for elastic fibre development in vivo. *Nature*. 2002;415(6868):168-171.
  59. Yokomizo T, Ogawa M, Osato M, et al. Requirement of *Runx1/AML1/PEBP2alphaB* for the generation of haematopoietic cells from endothelial cells. *Genes Cells*. 2001;6(1):13-23.
  60. Rybtsov S, Sobiesiak M, Taoudi S, et al. Hierarchical organization and early hematopoietic specification of the developing HSC lineage in the AGM region. *J Exp Med*. 2011;208(6):1305-1315.
  61. Rybtsov S, Batsivari A, Bilotkach K, et al. Tracing the origin of the HSC hierarchy reveals an SCF-dependent, IL-3-independent CD43(-) embryonic precursor. *Stem Cell Reports*. 2014;3(3):489-501.

62. Taoudi S, Gonneau C, Moore K, et al. Extensive hematopoietic stem cell generation in the AGM region via maturation of VE-cadherin+CD45+ pre-definitive HSCs. *Cell Stem Cell*. 2008;3(1):99-108.
63. dela Paz NG, D'Amore PA. Arterial versus venous endothelial cells. *Cell Tissue Res*. 2009;335(1):5-16.
64. Mass E, Ballesteros I, Farlik M, et al. Specification of tissue-resident macrophages during organogenesis. *Science*. 2016;353(6304):aaf4238.
65. Böiers C, Carrelha J, Lutteropp M, et al. Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells. *Cell Stem Cell*. 2013;13(5):535-548.
66. Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. *Nature*. 2013;502(7470):232-236.
67. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. *Annu Rev Cell Dev Biol*. 1995;11(1):549-599.
68. Mui KL, Chen CS, Assoian RK. The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces. *J Cell Sci*. 2016;129(6):1093-1100.
69. Porcheri C, Golan O, Calero-Nieto FJ, et al. Notch ligand Dll4 impairs cell recruitment to aortic clusters and limits blood stem cell generation. *EMBO J*. 2020;39(8):e104270.
70. Nostro MC, Cheng X, Keller GM, Gadue P. Wnt, activin, and BMP signaling regulate distinct stages in the developmental pathway from embryonic stem cells to blood. *Cell Stem Cell*. 2008;2(1):60-71.
71. Chanda B, Ditadi A, Iscove NN, Keller G. Retinoic acid signaling is essential for embryonic hematopoietic stem cell development. *Cell*. 2013;155(1):215-227.
72. Zape JP, Lizama CO, Cautivo KM, Zovein AC. Cell cycle dynamics and complement expression distinguishes mature haematopoietic subsets arising from homogenic endothelium. *Cell Cycle*. 2017;16(19):1835-1847.
73. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. *Curr Opin Cell Biol*. 2000;12(6):658-665.
74. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol*. 2000;182(3):311-322.
75. Sakaue-Sawano A, Yo M, Komatsu N, et al. Genetically encoded tools for optical dissection of the mammalian cell cycle. *Mol Cell*. 2017;68(3):626-640.e5.
76. Nottingham WT, Jarratt A, Burgess M, et al. Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer. *Blood*. 2007;110(13):4188-4197.
77. Ng CEL, Yokomizo T, Yamashita N, et al. A Runx1 intronic enhancer marks homogenic endothelial cells and hematopoietic stem cells. *Stem Cells*. 2010;28(10):1869-1881.
78. de Bruijn MFTR, Ma X, Robin C, Ottersbach K, Sanchez MJ, Dzierzak E. Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta. *Immunity*. 2002;16(5):673-683.
79. Li Y, Gao L, Hadland B, Tan K, Speck NA. CD27 marks murine embryonic hematopoietic stem cells and type II prehematopoietic stem cells. *Blood*. 2017;130(3):372-376.
80. Yang L, Bryder D, Adolfsson J, et al. Identification of Lin(-)Sca1(+)Kit(+)CD34(+)Flt3-short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. *Blood*. 2005;105(7):2717-2723.
81. Mead AJ, Neo WH, Barkas N, et al. Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation. *J Exp Med*. 2017;214(7):2005-2021.
82. Oatley M, Bölükbası ÖV, Svensson V, et al. Single-cell transcriptomics identifies CD44 as a marker and regulator of endothelial to haematopoietic transition. *Nat Commun*. 2020;11(1):586.
83. Yzaguirre AD, de Bruijn MFTR, Speck NA. The role of Runx1 in embryonic blood cell formation. *Adv Exp Med Biol*. 2017;962:47-64.
84. Goode DK, Obier N, Vijayabaskar MS, et al. Dynamic gene regulatory networks drive hematopoietic specification and differentiation. *Dev Cell*. 2016;36(5):572-587.
85. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell*. 2010;7(4):532-544.
86. Lie-A-Ling M, Marinopoulou E, Li Y, et al. RUNX1 positively regulates a cell adhesion and migration program in murine homogenic endothelium prior to blood emergence. *Blood*. 2014;124(11):e11-e20.
87. Lichtinger M, Ingram R, Hannah R, et al. RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis. *EMBO J*. 2012;31(22):4318-4333.
88. Tanaka Y, Joshi A, Wilson NK, Kinston S, Nishikawa S, Göttgens B. The transcriptional programme controlled by Runx1 during early embryonic blood development. *Dev Biol*. 2012;366(2):404-419.
89. Young DW, Hassan MQ, Pratap J, et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. *Nature*. 2007;445(7126):442-446.
90. Ali SA, Zaidi SK, Dacwag CS, et al. Phenotypic transcription factors epigenetically mediate cell growth control. *Proc Natl Acad Sci USA*. 2008;105(18):6632-6637.
91. Cai X, Gao L, Teng L, et al. Runx1 deficiency decreases ribosome biogenesis and confers stress resistance to hematopoietic stem and progenitor cells. *Cell Stem Cell*. 2015;17(2):165-177.
92. Himburg HA, Harris JR, Ito T, et al. Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. *Cell Rep*. 2012;2(4):964-975.
93. Ganuza M, Hadland B, Chabot A, et al. Murine homogenic endothelial precursors display heterogeneous hematopoietic potential ex vivo. *Exp Hematol*. 2017;51:25-35.e6.
94. Jokubaitis VJ, Sinka L, Driessen R, et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. *Blood*. 2008;111(8):4055-4063.
95. Sinka L, Biasch K, Khazaal I, Péault B, Taviani M. Angiotensin-converting enzyme (CD143) specifies emerging lympho-hematopoietic progenitors in the human embryo. *Blood*. 2012;119(16):3712-3723.
96. Bernstein KE, Berk BC. The biology of angiotensin II receptors. *Am J Kidney Dis*. 1993;22(5):745-754.
97. Crosse EI, Gordon-Keylock S, Rybtsov S, et al. Multi-layered spatial transcriptomics identify secretory factors promoting human hematopoietic stem cell development. *Cell Stem Cell*. 2020;27(5):822-839.e8.
98. Julien E, Biasch K, El Omar R, et al. Renin-angiotensin system is involved in embryonic emergence of hematopoietic stem/progenitor cells. *Stem Cells*. 2021;39(5):636-649.